Analyst Conference Summary

biotechnology

conference date: August 4, 2026 @ 1:30 PM Pacific Time
for quarter ending: June 30, 2026 (fiscal Q3, third quarter fiscal 2026)

Forward-looking statements

Overview: Early in commercial sales, continues to develop pipeline.

Basic data (GAAP):

Revenue was $ million, down sequentially from $74 million, and down from $ million year-earlier.

Net income was $ million, down sequentially from negative $133 million, way down from $ million year-earlier.

Diluted EPS was $ , down sequentially from negative $0.93, down from $ year-earlier.

Guidance:

none

Conference Highlights:

CEO Christopher Anzalone said ""

The comp with fiscal Q3 2025 was poor because in that quarter Arrowhead received $ million in upfront payments and milestones (but no sales).

In November 2025 the FDA approved Redemplo (plozasiran) for FCS (familial chylomicronemia syndrome). This is Arrowhead's first approved medicine. Has built out the sales and marketing teams for plozasiran. Feedback has been favorable. Helps to prevent pancreatitis from FCS. Lowered to $45,000 annual price, dosing every 3 months. Priced for the larger severe hypertriglyceridemia market (SHTG), where it is in Phase 3 trials which should report results in Q3 2026. Believes is best in class. To date patients treated, new prescription rate has increased to about per week.

Redemplo was approved in Australia in Q1 2026. Canada approved. The CHMP recommended EU approval. China approved. It will be marketed in Greater China by Sanofi under an agreement between Sanofi and Arrowhead.

In fiscal Q2 2026 licensed ARO-PNPLA3 to Madrigal Pharmaceuticals for MASH. Receiving $25 million upfront, up to $975 million in milestone payments, and tiere royalties if commercialized.

Expects novel dual dimer candidates in the clinic in 2027.

See also the Arrowhead Pharmaceuticals pipeline page.

Cash and equivalents (including investments) ended at $ billion, up sequentially from $1.78 million. $na million cash from operations. Debt of convertible notes is $ million.

Operating expenses of $ million included $ million for R&D and $ million for G&A. Leaving operating income of negative $ million. Other income $ million. Tax $0 million. Loss atributable to non-contolling interest $ million.

Q&A selective summary:

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: